Therapeutic HBV vaccine - GeneCure Biotechnologies
Latest Information Update: 18 Feb 2021
Price :
$50 *
At a glance
- Originator GeneCure Biotechnologies
- Class Antivirals; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 12 Feb 2021 HBV vaccine is available for licensing as of 12 Feb 2021. http://www.genecure.com/about-us.html
- 12 Feb 2021 GeneCure Biotechnologies has patent protection for SimVec gene transfer technology (GeneCure website, February 2021)
- 12 Feb 2021 Preclinical trials in Hepatitis B in USA (Parenteral), prior to February 2021 (GeneCure Biotechnologies pipeline, February 2021)